



# Rajiv Gandhi Cancer Institute and Research Centre

A Unit of Indraprastha Cancer Society  
Registered under "Societies Registration Act 1860"



Sector-V, Rohini, Delhi - 110 085

Tel: +91-11-4702 2222

Fax: +91-11-2705 1037

Web: www.rgcirc.org

## Institutional Review Board

### Rajiv Gandhi Cancer Institute & Research Centre

Nos. RGCIRC / IRB-BHR /48/ 2020

30/05/2020

Dr Shivendra Singh/ Dr Vineet Talwar/ Dr Abhishek Agarwal

Dept of Surgical Oncology/ Dept of Medical Oncology, RGCIRC

Sub: Res/SCM/38/2020/52: "Multimodality Management in gall bladder cancer - Experience from a tertiary care oncology centre in North India"

Dear Dr Shivendra Singh/ Dr Vineet Talwar/ Dr Abhishek Agarwal,

The Institutional Review Board- Biomedical Health Research (IRB-BHR) reviewed and discussed the Research Study to be conducted via expedited review process virtually ( during these COVID-19 times as per ICMR-BHR guidelines) titled "Multimodality Management in gall bladder cancer - Experience from a tertiary care oncology centre in North India" on 26<sup>th</sup> may 2020.

The following members attended the meeting to review the study:


S.NO	Name / Affiliations	Expertise
1.	Dr W. Selvamurthy, Chairman of IRB; Chairperson, Director General - Amity Directorate of Science & Innovation Chancellor, Amity University Chhattisgarh & Chair Professor for Life Sciences	Chairman
2.	Dr. Sunil . Khetarpal CTO,RGCIRC	Member Secretary
3.	Dr. Sudhir Rawal, Surgical Oncology , RGCIRC	Clinician
4.	Dr. Anurag Mehta, Department of Medical Laboratory	Clinician


IRB-BHR (IEC-II) has decided to approve the study to be conducted in its present form and given a waiver from consenting process.

Please also note that:

1. The IEC-II has applied for registration with DHR for Biomedical and Health Research vide application number : EC / NEW / INST/ 2020 / 774 dated 04<sup>th</sup> may2020.
2. It is certified that IRB-BHR of RGCIRC conforms to ICH-GCP, Indian council of Medical Research and New Drugs and Clinical Trials Guidelines and functions in accordance with its SOP.
3. The Institutional Review Board-BHR (IRB/IEC-II) expects to be informed about the progress of the study, any SAE occurring in the course of the study, any changes in the protocol and patient information / informed consent and requires to provide a copy of the final report.

Yours sincerely,

  
Dr. Sunil Kr. Khetarpal  
Convener IRB

  
1/6/2020